DaVita (NYSE:DVA - Get Free Report)'s stock had its "hold (c+)" rating reissued by analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.
A number of other research firms also recently weighed in on DVA. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Bank of America cut their target price on DaVita from $145.00 to $140.00 and set an "underperform" rating for the company in a research report on Wednesday, September 10th. Barclays cut their target price on DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Finally, Truist Financial set a $148.00 price target on DaVita in a research note on Friday, August 8th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, DaVita currently has an average rating of "Reduce" and an average price target of $158.00.
View Our Latest Report on DVA
DaVita Trading Down 2.4%
DaVita stock traded down $3.11 during mid-day trading on Wednesday, hitting $127.93. The company had a trading volume of 660,620 shares, compared to its average volume of 810,726. The stock's 50 day moving average price is $133.83 and its two-hundred day moving average price is $139.68. DaVita has a 12 month low of $126.07 and a 12 month high of $179.60. The company has a market capitalization of $9.15 billion, a PE ratio of 12.58, a price-to-earnings-growth ratio of 0.94 and a beta of 1.13.
DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping the consensus estimate of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The business had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same period in the previous year, the company posted $2.00 earnings per share. The company's revenue for the quarter was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Equities research analysts anticipate that DaVita will post 10.76 EPS for the current year.
Insider Activity
In related news, insider James O. Hearty sold 2,351 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares of the company's stock, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.50% of the company's stock.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Fifth Third Bancorp increased its holdings in DaVita by 5.0% during the 1st quarter. Fifth Third Bancorp now owns 4,274 shares of the company's stock worth $654,000 after purchasing an additional 204 shares during the period. Concurrent Investment Advisors LLC purchased a new position in DaVita during the 1st quarter worth $223,000. Wealth Enhancement Advisory Services LLC grew its stake in DaVita by 22.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company's stock worth $666,000 after buying an additional 800 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in DaVita by 7.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 55,255 shares of the company's stock worth $8,452,000 after buying an additional 4,048 shares during the last quarter. Finally, OneDigital Investment Advisors LLC purchased a new position in DaVita during the 1st quarter worth $200,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.
About DaVita
(
Get Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.